Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.
Phosphoglycerate kinase-1 is a predictor of poor survival and a novel prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.
复制标题
磷酸甘油酸激酶-1 是乳腺癌患者生存不良的预测因子，也是紫杉醇化疗耐药的新型预后生物标志物。
DOI：
10.1038/bjc.2015.114
复制
发表时间：
2015-04-14
影响因子：
8.8
通讯作者：
Pang, D.
中科院分区：
文献类型：
--
作者：
Sun, S.;Liang, X.;Zhang, X.;Liu, T.;Shi, Q.;Song, Y.;Jiang, Y.;Wu, H.;Jiang, Y.;Lu, X.;Pang, D.
磷酸甘油酸激酶-1 （PGK1）最近在各种恶性肿瘤中被证实；然而，可变PGK1表达的分子机制及其在生存状态方面的临床意义尚不清楚。采用实时荧光定量PCR （Real-time quantitative PCR, Real-time qPCR）和western blotting检测46例新鲜乳腺癌组织和匹配正常组织中PGK1的表达。采用免疫组化方法研究了包含401例乳腺癌组织和123例匹配正常组织的组织微阵列（TMA）中PGK1的表达。分析PGK1表达与临床病理特征的相关性。与正常乳腺组织相比，乳腺癌组织中PGK1 mRNA和蛋白的表达明显升高。PGK1高表达与较高的组织学分级（P=0.009）以及ER （P=0.004）、Her-2 （P=0.026）和P53 （P=0.012）的阳性状态显著相关。高水平的PGK1表达与较差的总生存相关（OS， P=0.02）。此外，接受紫杉醇化疗的高水平PGK1表达的患者的OS比低水平PGK1表达的患者短（P<0.001）。多因素分析表明，PGK1 （P=0.001）是紫杉醇治疗患者的独立预测因子。PGK1是乳腺癌紫杉醇化疗耐药的预后生物标志物。
Phosphoglycerate kinase-1 (PGK1) has been recently documented in various malignancies; however, the molecular mechanisms of the variable PGK1 expression and its clinical significance in terms of survival status remain unclear. Real-time quantitative PCR (real-time qPCR) and western blotting were used to verify PGK1 expression in 46 fresh breast cancer tissues and matched normal tissues. A tissue microarray (TMA) comprising 401 breast cancer tissues and 123 matched normal tissues was investigated by immunohistochemistry for PGK1 expression. Then, the correlation between PGK1 expression and the clinicopathologic features was analysed. PGK1 mRNA and protein expression were significantly increased in breast cancer tissues compared with that in normal breast tissues. High PGK1 expression was significantly associated with higher histologic grade (P=0.009) and positive status of ER (P=0.004), Her-2 (P=0.026) and P53 (P=0.012). High levels of PGK1 expression were associated with worse overall survival (OS, P=0.02). Furthermore, patients who underwent paclitaxel chemotherapy with high levels PGK1 expression had shorter OS than did those with low levels of PGK1 expression (P<0.001). Multivariate analysis indicated that PGK1 (P=0.001) was an independent predictor in the patients treated with paclitaxel. PGK1 is a prognostic biomarker of chemoresistance to paclitaxel treatment in breast cancer.
登录
查看更多内容
影响因子：
3.8
作者：
Kessler J;Hahnel A;Wichmann H;Rot S;Kappler M;Bache M;Vordermark D
通讯作者：
Vordermark D
DOI：
10.1016/j.bbamcr.2003.11.004
发表时间：
2004-04-01
影响因子：
5.1
作者：
Daly, EB;Wind, T;Hogg, PJ
通讯作者：
Hogg, PJ
DOI：
10.1016/s0167-4781(97)00229-7
发表时间：
1998-04-01
期刊：
BIOCHIMICA ET BIOPHYSICA ACTA-GENE STRUCTURE AND EXPRESSION
影响因子：
--
作者：
Popanda, O;Fox, G;Thielmann, HW
通讯作者：
Thielmann, HW
影响因子：
8.8
作者：
通讯作者：
--
影响因子：
--
作者：
Ai, Jianzhong;Huang, Huizhe;Zhou, Qin
通讯作者：
Zhou, Qin